Suzhou Boten has received CNY 520 million in series B round of funding on August 21, 2022. The transaction included participation from Hillhouse Investment Management, Ltd., Guotou China Merchant Investment Management Co., Ltd. through its fund, Advanced Manufacturing Industrial Investment Fund Phase II (Limited Partnership), Huimei Capital, Yuemin Investment, Shanghai Chuangfeng Medico Private Equity Fund, Huashan Ruilian Fund Management Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., China Merchants Capital Investment Co., Ltd., China Merchants Securities Co., Ltd. and other investors.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.67 CNY | -0.17% | +4.09% | -5.43% |
04-30 | Fosun Pharma's Q1 Profit Slumps 38% | MT |
04-29 | Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.43% | 7.8B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Suzhou Boten announced that it has received CNY 520 million in funding from a group of investors